Currently Enrolling at UCSF:
A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06961006
Sponsor: Merck Sharp & Dohme LLC
PI: Adil Daud, MD
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
NCT06413680
Sponsor: Regeneron Pharmaceuticals
PI: Adil Daud, MD
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies (ARTACUS)
NCT04349436
Sponsor: Replimune Inc.
PI: Katy Tsai, MD
A Study of IBI363 in Subjects with Advanced Solid Malignancies
NCT06281678
Sponsor: Innovent Biologics
PI: Katy Tsai, MD
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674
Sponsor: Nurix Therapeutics, Inc.
PI: Pamela Munster, MD
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067
Sponsor: Erasca, Inc.
PI: Adil Daud, MD
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797
Sponsor: Fore Biotherapeutics
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285
Sponsor: Pierre Fabre Medicament
PI: Adil Daud, MD
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
NCT06326411
Sponsor: Nested Therapeutics, Inc
PI: Varun Monga, MD
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
NCT06799533
Sponsor: Pfizer
PI: Adil Daud, MD
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916
Sponsor: Regeneron Pharmaceuticals
PI: Katy Tsai, MD
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951
Sponsor: Replimune Inc.
PI: Adil Daud, MD
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
NCT04598009
Sponsor: Pfizer
PI: Katy Tsai, MD
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332
Sponsor: IDEAYA Biosciences
PI: Katy Tsai, MD
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
NCT06947928
Sponsor: TuHURA Biosciences, Inc.
PI: Adil Daud, MD
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
NCT03589339
Sponsor: Nanobiotix
PI: Jason Chan, MD
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
NCT05105100
Sponsor: University of California, San Francisco
PI: Adil Daud, MD
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
NCT06028074
Sponsor: Georgiamune Inc.
PI: Katy Tsai, MD
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926
Sponsor: Georgiamune Inc.
PI: Katy Tsai, MD
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
NCT06287463
Sponsor: Deciphera Pharmaceuticals
PI: Rahul Aggarwal, MD
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697
Sponsor: ModernaTX, Inc.
PI: Adil Daud, MD
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Sponsor: Replimune Inc.
PI: Katy Tsai, MD
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT04851119
Sponsor: Children's Oncology Group
PI: Kieuhoa T. Vo, MD
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT05111574
Sponsor: National Cancer Institute (NCI)
PI: Katy Tsai, MD
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
NCT06264180
Sponsor: Replimune Inc.
PI: Katy Tsai, MD